English  |  正體中文  |  简体中文  |  Items with full text/Total items : 17938/22957 (78%)
Visitors : 7396065      Online Users : 247
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/24684


    Title: Cardiovascular Protection of Hydroxychloroquine in Patients with Sjogren's Syndrome
    Authors: Yang, DH;Wang, YH;Pan, LF;Wei, JCC
    Keywords: Sjö gren’ s syndrome;hydroxychloroquine;inflammation;coronary artery disease;cardiovascular event;autoimmune
    Date: 2020
    Issue Date: 2022-08-09T08:06:21Z (UTC)
    Publisher: MDPI
    Abstract: Sjogren's syndrome (SS) is a chronic systemic inflammation disease with clinical presentation of dry eye, dry mouth, and polyarthralgia. Active inflammation is associated with an increased risk of associated arterial stiffness or subclinical atherosclerosis-related cardiovascular events. We used the longitudinal health insurance database of Taiwan, which includes one million participants, to evaluate the relationship between the clinical medication of hydroxychloroquine (HCQ) and the development of coronary artery disease (CAD). In total, 1674 patients with SS receiving HCQ medication were included after exclusion for previous CAD. Altogether, 1142 SS patients were included for evaluation after follow-up for more than one year. After adjusting for age, gender, medications, and chronic comorbidities, a significantly decreased hazard ratio (HR) for developing CAD was found among SS patients with higher medication possession ratio (MPR) of HCQ (HR = 0.49, 95% confidence interval, CI: 0.26-0.94) when compared with low MPR of HCQ. A low HR for CAD was observed in SS patients with a high cumulative dose of at least 100,267 mg of HCQ (HR = 0.25, 95% CI: 0.09-0.66). Long-term HCQ therapy may decrease the HR of CAD in SS patients. The significant cardiovascular protective effect of HCQ therapy was observed in our study.
    URI: http://dx.doi.org/10.3390/jcm9113469
    https://www.webofscience.com/wos/woscc/full-record/WOS:000593208800001
    https://ir.csmu.edu.tw:8080/handle/310902500/24684
    Relation: JOURNAL OF CLINICAL MEDICINE ,2020 ,v9 ,issue 11
    Appears in Collections:[中山醫學大學研究成果] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML191View/Open


    SFX Query

    All items in CSMUIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback